Your session is about to expire
← Back to Search
Tafasitamab + Lenalidomide for Diffuse Large B-Cell Lymphoma (frontMIND Trial)
frontMIND Trial Summary
This trial is testing a new antibody to treat DLBCL, a type of blood cancer. The trial will compare the new treatment to the standard of care to see if it is more effective with fewer side effects.
frontMIND Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 81 Patients • NCT02399085frontMIND Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My lymphoma type is not specifically listed.My cancer has spread to my brain.I am considered a suitable candidate for R-CHOP treatment.I can take care of myself and perform daily activities.I have received treatments for lymphoma before the start of this clinical trial.I have had cancer before, but it wasn't related to blood.My lymphoma is CD20-positive and has not been treated yet.I do not have any major heart, brain, or systemic diseases that could affect my participation.I am allergic or cannot tolerate the drugs in R-CHOP.I currently have an active infection.My lymphoma diagnosis matches the 2016 WHO classification.I can provide samples of my tumor for testing.My blood counts are within a healthy range.My cancer severity score fits the trial's requirements.I agree to use condoms and not donate sperm.
- Group 1: Tafasitamab plus lenalidomide in addition to R-CHOP
- Group 2: Tafasitamab placebo plus lenalidomide placebo in addition to R-CHOP
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Which patients are eligible for this clinical trial?
"This clinical trial is looking for 880 individuals that have b-cell lymphoma and are aged between 18 and 80. Furthermore, potential participants must meet the following conditions: IPI status of 3 to 5 (for patients > 60 years of age) or aaIPI 2 to 3 (for patients ≤ 60 years of age), DLBCL, NOS including GCB type, ABC type, High-grade BCL with MYC and B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangements (double-hit or triple-hit lymphoma"
What indications does Tafasitamab typically address?
"Tafasitamab is most often used as a leukemia treatment, but it can also be taken for other issues such as ophthalmia, sympathetic, at least two prior systemic chemotherapy regimens, and lung cancers."
Does this medical experiment have an age limit?
"This trial is currently enrolling individuals who are over the age of 18 and below 80 years old."
Are patients currently being enrolled in this research program?
"As of 8/23/2022, this study is still open and actively recruiting patients according to the listing on clinicaltrials.gov. This particular trial was first posted on 5/11/21."
Does Tafasitamab have the green light from the FDA?
"There is some efficacy data from earlier phases as well as multiple rounds of safety testing, so Tafasitamab gets a 3 for safety."
Could you share the aggregate patient number for this clinical trial?
"That is accurate. The information available on clinicaltrials.gov reveals that this study, which was originally posted on May 11th 2021, is still recruiting patients. 880 individuals are needed for the trial and 100 different sites are being utilized."
In how many different medical clinics is this trial being offered?
"One hundred different medical facilities are conducting this trial. If you wish to enroll and minimize the burden of travel, pick a location nearest to where you live from the following cities: Fort Worth, Charlotte, Sioux Falls or any of the other 100 locations."
Are there other examples of Tafasitamab's efficacy?
"Tafasitamab's first clinical trial took place in 1993 at the National Institutes of Health Clinical Center. As of now, a total of 2685 trials have been completed with 1669 still active. A considerable amount of these ongoing studies are based out of Fort Worth, Texas."
Share this study with friends
Copy Link
Messenger